Fc-fusion technology and recombinant FVIII and FIX in the management of the hemophilias
Maria Elisa Mancuso,1 Pier Mannuccio Mannucci21Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, 2Scientific Direction, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, ItalyAbstract: Prophylaxis with regular infusions of factor VIII (FVIII)- or factor IX (FIX)- conta...
Saved in:
Main Authors: | Mancuso ME (Author), Mannucci PM (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2014-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comparative evaluation of the safety and efficacy of recombinant FVIII in severe hemophilia A patients
by: Hassan Abolghasemi, MD, et al.
Published: (2018) -
Albumin-Fusion Recombinant FIX in the Management of People with Hemophilia B: An Evidence-Based Review
by: Pasca S, et al.
Published: (2022) -
GlycoPEGylated recombinant factor IX for hemophilia B in context
by: Santagostino E, et al.
Published: (2018) -
Exploration of the minimum necessary FVIII level at different physical activity levels in pediatric patients with hemophilia A
by: Di Ai, et al.
Published: (2022) -
PBPK modeling of recombinant factor IX Fc fusion protein (rFIXFc) and rFIX to characterize the binding to type 4 collagen in the extravascular space
by: Michael E. Cloesmeijer, et al.
Published: (2024)